Pharma

Your Article Summary

See Latest Articles

Abbott Adds Hepatitis B Test to its Broad Menu of Immunoassays on the ARCHITECT i 2000 and i 2000SR
Abbott, 05/15/09

Abbott announced that it has received premarket approval from the U.S. Food and Drug Administration for ARCHITECT CORE, an automated hepatitis B test for use on its ARCHITECT i 2000 and i 2000SR immunoassay testing instruments. ARCHITECT CORE is a chemiluminescent microparticle immunoassay for the qualitative detection of IgG and IgM antibodies to hepatitis B core antigen in human adult and pediatric serum and plasma and neonatal serum. It is intended as an aid in diagnosis of acute, chronic or resolved hepatitis B virus infection in conjunction with other laboratory results and clinical information.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Recombinant Human Erythropoietin, Epogin Injection Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09

Synthon announces European approvals for Raloxifene
Synthon, 12/08/09

US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09

 See all of Drug/Product Approvals